{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T16:42:21Z","timestamp":1790095341024,"version":"4.0.1"},"reference-count":279,"publisher":"Impact Journals, LLC","issue":"58","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2017,11,17]]},"DOI":"10.18632\/oncotarget.21837","type":"journal-article","created":{"date-parts":[[2017,10,16]],"date-time":"2017-10-16T19:12:57Z","timestamp":1508181177000},"page":"99179-99202","source":"Crossref","is-referenced-by-count":53,"title":["Phosphodiesterase type 5 and cancers: progress and challenges"],"prefix":"10.18632","volume":"8","author":[{"given":"Ines","family":"Barone","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, Arcavacata di Rende, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinzia","family":"Giordano","sequence":"additional","affiliation":[{"name":"Centro Sanitario, University of Calabria, Arcavacata di Rende, CS, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Bonofiglio","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, Arcavacata di Rende, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastiano","family":"And\u00f2","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, Arcavacata di Rende, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Catalano","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, Arcavacata di Rende, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2017,10,12]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3322\/caac.21262","article-title":"Global cancer statistics, 2012","volume":"65","author":"Jemal","year":"2015","journal-title":"CA Cancer J Clin"},{"key":"2","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1158\/1055-9965.EPI-15-0578","article-title":"Global cancer incidence and mortality rates and trends - an update","volume":"25","author":"Jemal","year":"2016","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"3","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.soncn.2015.02.003","article-title":"Systemic treatment for breast cancer: Chemotherapy and biotherapy agents","volume":"31","author":"Liu","year":"2015","journal-title":"Semin Oncol Nurs"},{"key":"4","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1177\/107327481402100104","article-title":"Systemic and targeted therapies for early-stage lung cancer","volume":"21","author":"Pinder-Schenck","year":"2014","journal-title":"Cancer Control"},{"key":"5","doi-asserted-by":"crossref","first-page":"673","DOI":"10.4254\/wjh.v7.i4.673","article-title":"Recent advances in multidisciplinary management of hepatocellular carcinoma","volume":"7","author":"Waked","year":"2015","journal-title":"World J Hepatol"},{"key":"6","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/iju.13091","article-title":"Current status of primary pharmacotherapy and future perspectives toward upfront therapy for metastatic hormone-sensitive prostate cancer","volume":"23","author":"Eto","year":"2016","journal-title":"Int J Urol"},{"key":"7","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1158\/1078-0432.CCR-15-1900","article-title":"Expression and function of phosphodiesterase type 5 in human breast cancer cell lines and tissues: Implications for targeted therapy","volume":"22","author":"And\u00f2","year":"2016","journal-title":"Clin Cancer Res"},{"key":"8","first-page":"3961","article-title":"Exisulind, a novel proapoptotic drug, inhibits rat urinary bladder tumorigenesis","volume":"61","author":"Grubbs","year":"2001","journal-title":"Cancer Res"},{"key":"9","doi-asserted-by":"crossref","first-page":"3454","DOI":"10.1200\/JCO.2003.02.114","article-title":"Phase I and II study of exisulind in combination with capecitabine in patients with metastatic breast cancer","volume":"21","author":"Valero","year":"2003","journal-title":"J Clin Oncol"},{"key":"10","first-page":"479","article-title":"Exisulind-induced apoptosis in a non-small cell lung cancer orthotopic lung tumor model augments docetaxel treatment and contributes to increased survival","volume":"2","author":"Thompson","year":"2003","journal-title":"Mol Cancer Ther"},{"key":"11","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1517\/13543780903485642","article-title":"Targeting cancer with phosphodiesterase inhibitors","volume":"19","author":"Schermuly","year":"2010","journal-title":"Expert Opin Investig Drugs"},{"key":"12","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s40139-015-0083-1","article-title":"Phosphodiesterase type 5 as a candidate therapeutic target in cancers","volume":"3","author":"And\u00f2","year":"2015","journal-title":"Curr Pathobiol Rep"},{"key":"13","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1210\/er.2013-1053","article-title":"Clinical and molecular genetics of the phosphodiesterases (PDEs)","volume":"35","author":"Stratakis","year":"2014","journal-title":"Endocr Rev"},{"key":"14","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1095\/biolreprod67.2.423","article-title":"Presence of cyclic nucleotide phosphodiesterases PDE1A, existing as a stable complex with calmodulin, and PDE3a in human spermatozoa","volume":"67","author":"Gagnon","year":"2002","journal-title":"Biol Reprod"},{"key":"15","first-page":"495","article-title":"Regulatory roles of adenylate cyclase and cyclic nucleotide phosphodiesterases 1 and 4 in interleukin-13 production by activated human T cells","volume":"62","author":"Watanabe","year":"2001","journal-title":"Biochem Pharmacol"},{"key":"16","article-title":"Assays for cyclic nucleotide-specific phosphodiesterases (PDEs) in the central nervous system (PDE1, PDE2, PDE4, and PDE10)","author":"De Vivo","year":"2007","journal-title":"Curr Protoc Neurosci"},{"key":"17","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1161\/01.RES.0000215576.27615.fd","article-title":"Role of nuclear Ca2+\/calmodulin-stimulated phosphodiesterase 1A in vascular smooth muscle cell growth and survival","volume":"98","author":"Yan","year":"2006","journal-title":"Circ Res"},{"key":"18","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1161\/hh0202.104108","article-title":"Cyclic nucleotide phosphodiesterase 1c promotes human arterial smooth muscle cell proliferation","volume":"90","author":"Bornfeldt","year":"2002","journal-title":"Circ Res"},{"key":"19","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.2174\/138161210790963760","article-title":"Cyclic nucleotide phosphodiesterases (PDE) and peptide motifs","volume":"16","author":"Lugnier","year":"2010","journal-title":"Curr Pharm Des"},{"key":"20","doi-asserted-by":"crossref","first-page":"4812","DOI":"10.1111\/j.1742-4658.2007.06001.x","article-title":"Characterization of inhibitors of phosphodiesterase 1c on a human cellular system","volume":"274","author":"Hatzelmann","year":"2007","journal-title":"FEBS J"},{"key":"21","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s00213-008-1273-x","article-title":"Selective phosphodiesterase inhibitors: a promising target for cognition enhancement","volume":"202","author":"Prickaerts","year":"2009","journal-title":"Psychopharmacology (Berl)"},{"key":"22","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/S0006-2952(98)00331-1","article-title":"Cyclic nucleotide phosphodiesterase (PDE) inhibitors and immunomodulation","volume":"57","author":"Essayan","year":"1999","journal-title":"Biochem Pharmacol"},{"key":"23","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.coph.2011.09.002","article-title":"PDE1 isozymes, key regulators of pathological vascular remodeling","volume":"11","author":"Yan","year":"2011","journal-title":"Curr Opin Pharmacol"},{"key":"24","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3389\/fnins.2011.00021","article-title":"Therapeutic utility of phosphodiesterase type I inhibitors in neurological conditions","volume":"5","author":"Medina","year":"2011","journal-title":"Front Neurosci"},{"key":"25","doi-asserted-by":"crossref","first-page":"6522","DOI":"10.1016\/j.bmcl.2013.10.014","article-title":"PDE2 inhibition: Potential for the treatment of cognitive disorders","volume":"23","author":"Breitenbucher","year":"2013","journal-title":"Bioorg Med Chem Lett"},{"key":"26","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1161\/01.RES.0000200178.34179.93","article-title":"Compartmentalized phosphodiesterase-2 activity blunts beta-adrenergic cardiac inotropy via an NO\/cGMP-dependent pathway","volume":"98","author":"Zaccolo","year":"2006","journal-title":"Circ Res"},{"key":"27","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1177\/002215549904700707","article-title":"Differential expression of the cyclic GMP-stimulated phosphodiesterase PDE2a in human venous and capillary endothelial cells","volume":"47","author":"Wolda","year":"1999","journal-title":"J Histochem Cytochem"},{"key":"28","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1111\/j.1742-4658.2008.06839.x","article-title":"cGMP-dependent protein kinase II and aldosterone secretion","volume":"276","author":"Hofmann","year":"2009","journal-title":"FEBS J"},{"key":"29","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1111\/j.1476-5381.2011.01729.x","article-title":"Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: Benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments","volume":"165","author":"Lugnier","year":"2012","journal-title":"Br J Pharmacol"},{"key":"30","doi-asserted-by":"crossref","first-page":"6823","DOI":"10.1074\/jbc.272.11.6823","article-title":"Structure, localization, and regulation of cGMP-inhibited phosphodiesterase (PDE3)","volume":"272","author":"Manganiello","year":"1997","journal-title":"J Biol Chem"},{"key":"31","doi-asserted-by":"crossref","first-page":"206","DOI":"10.2174\/187152509789105453","article-title":"Phosphodiesterase 3 (PDE3): Structure, localization and function","volume":"7","author":"Tagawa","year":"2009","journal-title":"Cardiovasc Hematol Agents Med Chem"},{"key":"32","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1161\/CIRCRESAHA.111.300003","article-title":"Phosphodiesterase type 3A regulates basal myocardial contractility through interacting with sarcoplasmic reticulum calcium atpase type 2A signaling complexes in mouse heart","volume":"112","author":"Backx","year":"2013","journal-title":"Circ Res"},{"key":"33","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.coph.2011.10.006","article-title":"Role of PDE3a in regulation of cell cycle progression in mouse vascular smooth muscle cells and oocytes: Implications in cardiovascular diseases and infertility","volume":"11","author":"Manganiello","year":"2011","journal-title":"Curr Opin Pharmacol"},{"key":"34","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1038\/ajh.2010.153","article-title":"Neuronal nitric oxide synthase supports renin release during sodium restriction through inhibition of phosphodiesterase 3","volume":"23","author":"Persson","year":"2010","journal-title":"Am J Hypertens"},{"key":"35","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.1365-2125.2010.03828.x","article-title":"Phosphodiesterase PDE inhibitors in the treatment of lower urinary tract dysfunction","volume":"72","author":"Oelke","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"36","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1016\/j.bmc.2012.01.033","article-title":"Phosphodiesterase inhibitors. Part 3: Design, synthesis and structure-activity relationships of dual PDE3\/4-inhibitory fused bicyclic heteroaromatic-dihydropyridazinones with anti-inflammatory and bronchodilatory activity","volume":"20","author":"Kohno","year":"2012","journal-title":"Bioorg Med Chem"},{"key":"37","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1159\/000054386","article-title":"Role of phosphodiesterases in the regulation of gonadotropin- releasing hormone secretion in GT1 cells","volume":"68","author":"Weiner","year":"1998","journal-title":"Neuroendocrinology"},{"key":"38","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.pupt.2010.12.011","article-title":"PDE4-inhibitors: A novel, targeted therapy for obstructive airways disease","volume":"24","author":"Spina","year":"2011","journal-title":"Pulm Pharmacol Ther"},{"key":"39","first-page":"197","article-title":"Phosphodiesterase 4 and its inhibitors in inflammatory diseases","volume":"35","author":"Lin","year":"2012","journal-title":"Chang Gung Med J"},{"key":"40","first-page":"259","article-title":"Differential expression and function of PDE8 and PDE4 in effector t cells: Implications for PDE8 as a drug target in inflammation","volume":"7","author":"Brocke","year":"2016","journal-title":"Front Pharmacol"},{"key":"41","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1517\/14728222.2013.818656","article-title":"PDE4 as a target for cognition enhancement","volume":"17","author":"Conti","year":"2013","journal-title":"Expert Opin Ther Targets"},{"key":"42","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s00395-010-0138-8","article-title":"Conserved expression and functions of PDE4 in rodent and human heart","volume":"106","author":"Conti","year":"2011","journal-title":"Basic Res Cardiol"},{"key":"43","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.biopsych.2012.04.030","article-title":"Downregulation of brain phosphodiesterase type IV measured with 11c-(r)-rolipram positron emission tomography in major depressive disorder","volume":"72","author":"Zarate","year":"2012","journal-title":"Biol Psychiatry"},{"key":"44","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1124\/mol.105.015719","article-title":"The long and short of vascular smooth muscle phosphodiesterase-4 as a putative therapeutic target","volume":"68","author":"Houslay","year":"2005","journal-title":"Mol Pharmacol"},{"key":"45","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1210\/en.2004-0562","article-title":"Pharmacological inhibition of phosphodiesterase 4 triggers ovulation in follicle-stimulating hormone-primed rats","volume":"146","author":"Palmer","year":"2005","journal-title":"Endocrinology"},{"key":"46","first-page":"391","article-title":"Phosphodiesterase inhibitors in the treatment of inflammatory diseases","author":"Spina","year":"2011","journal-title":"Handb Exp Pharmacol"},{"key":"47","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ejphar.2007.12.017","article-title":"PDE4 and PDE5 regulate cyclic nucleotides relaxing effects in human umbilical arteries","volume":"582","author":"Verde","year":"2008","journal-title":"Eur J Pharmacol"},{"key":"48","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.nlm.2012.02.008","article-title":"Phosphodiesterase type 5 (PDE5) inhibition improves object recognition memory: Indications for central and peripheral mechanisms","volume":"97","author":"Prickaerts","year":"2012","journal-title":"Neurobiol Learn Mem"},{"key":"49","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1358\/mf.2004.26.10.872561","article-title":"Phosphodiesterase 5 enzyme and its inhibitors: Update on pharmacological and therapeutical aspects","volume":"26","author":"Patil","year":"2004","journal-title":"Methods Find Exp Clin Pharmacol"},{"key":"50","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1749-6632.2010.05801.x","article-title":"Effect of dipyridamole during acute stroke: Exploring antithrombosis and neuroprotective benefits","volume":"1207","author":"Lee","year":"2010","journal-title":"Ann N Y Acad Sci"},{"key":"51","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00296-006-0212-6","article-title":"Adenosine and cytokine levels following treatment of rheumatoid arthritis with dipyridamole","volume":"27","author":"Darlington","year":"2006","journal-title":"Rheumatol Int"},{"key":"52","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s10585-012-9506-0","article-title":"Dipyridamole prevents triple-negative breast-cancer progression","volume":"30","author":"Zollo","year":"2013","journal-title":"Clin Exp Metastasis"},{"key":"53","first-page":"371","article-title":"Role of phosphodiesterase 5 in synaptic plasticity and memory","volume":"4","author":"Palmeri","year":"2008","journal-title":"Neuropsychiatr Dis Treat"},{"key":"54","doi-asserted-by":"crossref","first-page":"437","DOI":"10.2174\/156802607779941198","article-title":"The novel functions of cGMP-specific phosphodiesterase 5 and its inhibitors in carcinoma cells and pulmonary\/cardiovascular vessels","volume":"7","author":"Strada","year":"2007","journal-title":"Curr Top Med Chem"},{"key":"55","first-page":"e30","article-title":"Emerging new uses of phosphodiesterase-5 inhibitors in cardiovascular diseases","volume":"16","author":"Xi","year":"2011","journal-title":"Exp Clin Cardiol"},{"key":"56","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.pharmthera.2014.10.003","article-title":"PDE5 inhibitors as therapeutics for heart disease, diabetes and cancer","volume":"147","author":"Kukreja","year":"2015","journal-title":"Pharmacol Ther"},{"key":"57","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1161\/CIRCHEARTFAILURE.110.944694","article-title":"PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure: Results of a 1-year, prospective, randomized, placebo-controlled study","volume":"4","author":"Guazzi","year":"2011","journal-title":"Circ Heart Fail"},{"key":"58","doi-asserted-by":"crossref","first-page":"33252","DOI":"10.1074\/jbc.M111.259101","article-title":"Rod phosphodiesterase-6 (PDE6) catalytic subunits restore cone function in a mouse model lacking cone PDE6 catalytic subunit","volume":"286","author":"Ramamurthy","year":"2011","journal-title":"J Biol Chem"},{"key":"59","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1038\/sj.ijir.3901212","article-title":"Characteristics of photoreceptor PDE (PDE6): Similarities and differences to PDE5","volume":"16","author":"Cote","year":"2004","journal-title":"Int J Impot Res"},{"key":"60","doi-asserted-by":"crossref","first-page":"3305","DOI":"10.1021\/bi027095x","article-title":"Mutation in rod PDE6 linked to congenital stationary night blindness impairs the enzyme inhibition by its gamma-subunit","volume":"42","author":"Artemyev","year":"2003","journal-title":"Biochemistry"},{"key":"61","doi-asserted-by":"crossref","first-page":"15","DOI":"10.4161\/cl.19804","article-title":"Greasing the protein biosynthesis machinery of photoreceptor neurons: Role for postprenylation processing of proteins","volume":"2","author":"Ramamurthy","year":"2012","journal-title":"Cell Logist"},{"key":"62","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.bbrc.2006.04.143","article-title":"Phosphodiesterase 8 (PDE8) regulates chemotaxis of activated lymphocytes","volume":"345","author":"Brocke","year":"2006","journal-title":"Biochem Biophys Res Commun"},{"key":"63","doi-asserted-by":"crossref","first-page":"19925","DOI":"10.1073\/pnas.0609483103","article-title":"Modulation of leydig cell function by cyclic nucleotide phosphodiesterase 8A","volume":"103","author":"Beavo","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"64","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1016\/j.ajhg.2008.04.019","article-title":"Phosphodiesterase 8B gene variants are associated with serum TSH levels and thyroid function","volume":"82","author":"Mulas","year":"2008","journal-title":"Am J Hum Genet"},{"key":"65","doi-asserted-by":"crossref","first-page":"21826","DOI":"10.1038\/srep21826","article-title":"Discovery of novel PDE9 inhibitors capable of inhibiting A\u03b2 aggregation as potential candidates for the treatment of Alzheimer's disease","volume":"6","author":"Luo","year":"2016","journal-title":"Sci Rep"},{"key":"66","doi-asserted-by":"crossref","first-page":"9068","DOI":"10.1523\/JNEUROSCI.21-22-09068.2001","article-title":"Expression of cGMP-specific phosphodiesterase 9A mRNA in the rat brain","volume":"21","author":"Rosenberg","year":"2001","journal-title":"J Neurosci"},{"key":"67","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.bbr.2012.08.019","article-title":"Inhibition of phoshodiesterase type 2 or type 10 reverses object memory deficits induced by scopolamine or MK-801","volume":"236","author":"Prickaerts","year":"2013","journal-title":"Behav Brain Res"},{"key":"68","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1074\/jbc.M111.263806","article-title":"Activation of PDE10 and PDE11 phosphodiesterases","volume":"287","author":"Russwurm","year":"2012","journal-title":"J Biol Chem"},{"key":"69","doi-asserted-by":"crossref","first-page":"5301","DOI":"10.1158\/0008-5472.CAN-09-0884","article-title":"Functional phosphodiesterase 11A mutations may modify the risk of familial and bilateral testicular germ cell tumors","volume":"69","author":"Moran","year":"2009","journal-title":"Cancer Res"},{"key":"70","doi-asserted-by":"crossref","first-page":"E135","DOI":"10.1210\/jc.2010-1655","article-title":"Phosphodiesterase 11A (PDE11A) genetic variants may increase susceptibility to prostatic cancer","volume":"96","author":"Bendhack","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"71","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/sj.ijir.3901304","article-title":"Inhibition of phosphodiesterase 11 (PDE11) impacts on sperm quality","volume":"17","author":"Morelli","year":"2005","journal-title":"Int J Impot Res"},{"key":"72","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/S0022-5347(01)68504-5","article-title":"Phosphodiesterase 11 (PDE11) regulation of spermatozoa physiology","volume":"174","author":"Seftel","year":"2005","journal-title":"J Urol"},{"key":"73","first-page":"121","article-title":"Structural insight into the substrate specificity of phosphodiesterases","author":"Ye","year":"2011","journal-title":"Handb Exp Pharmacol"},{"key":"74","first-page":"1","article-title":"Cyclic nucleotide phosphodiesterases: Relating structure and function","volume":"65","author":"Corbin","year":"2001","journal-title":"Prog Nucleic Acid Res Mol Biol"},{"key":"75","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1124\/pr.58.3.5","article-title":"Cyclic nucleotide phosphodiesterases: Molecular regulation to clinical use","volume":"58","author":"Beavo","year":"2006","journal-title":"Pharmacol Rev"},{"key":"76","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1152\/physrev.00030.2010","article-title":"Mammalian cyclic nucleotide phosphodiesterases: Molecular mechanisms and physiological functions","volume":"91","author":"Corbin","year":"2011","journal-title":"Physiol Rev"},{"key":"77","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1126\/science.1112915","article-title":"DISC1 and PDE4B are interacting genetic factors in schizophrenia that regulate cAMP signaling","volume":"310","author":"Brandon","year":"2005","journal-title":"Science"},{"key":"78","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1146\/annurev.biochem.76.060305.150444","article-title":"Biochemistry and physiology of cyclic nucleotide phosphodiesterases: Essential components in cyclic nucleotide signaling","volume":"76","author":"Beavo","year":"2007","journal-title":"Annu Rev Biochem"},{"key":"79","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1056\/NEJMc0706182","article-title":"Mutation in PDE8B, a cyclic AMP-specific phosphodiesterase in adrenal hyperplasia","volume":"358","author":"Stratakis","year":"2008","journal-title":"N Engl J Med"},{"key":"80","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1046\/j.1432-1327.1998.2550391.x","article-title":"Expression, structure and chromosomal localization of the human cGMP-binding cGMP-specific phosphodiesterase PDE5A gene","volume":"255","author":"Omori","year":"1998","journal-title":"Eur J Biochem"},{"key":"81","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1038\/sj.ijir.3901207","article-title":"Tissue expression, distribution, and regulation of PDE5","volume":"16","author":"Lin","year":"2004","journal-title":"Int J Impot Res"},{"key":"82","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1006\/bbrc.2000.2186","article-title":"Identification of three alternative first exons and an intronic promoter of human PDE5A gene","volume":"268","author":"Lue","year":"2000","journal-title":"Biochem Biophys Res Commun"},{"key":"83","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1006\/bbrc.2000.4220","article-title":"Identification and regulation of human PDE5A gene promoter","volume":"280","author":"Lue","year":"2001","journal-title":"Biochem Biophys Res Commun"},{"key":"84","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1006\/bbrc.2000.4221","article-title":"Regulation of human PDE5A2 intronic promoter by cAMP and cGMP: Identification of a critical sp1-binding site","volume":"280","author":"Lue","year":"2001","journal-title":"Biochem Biophys Res Commun"},{"key":"85","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/sj.ijir.3900802","article-title":"Human PDE5A gene encodes three PDE5 isoforms from two alternate promoters","volume":"14","author":"Lue","year":"2002","journal-title":"Int J Impot Res"},{"key":"86","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/S0968-0004(97)01148-1","article-title":"The gaf domain: An evolutionary link between diverse phototransducing proteins","volume":"22","author":"Ponting","year":"1997","journal-title":"Trends Biochem Sci"},{"key":"87","doi-asserted-by":"crossref","first-page":"2760","DOI":"10.1046\/j.1432-1327.2000.01297.x","article-title":"Phosphorylation of phosphodiesterase-5 by cyclic nucleotide-dependent protein kinase alters its catalytic and allosteric cGMP-binding activities","volume":"267","author":"Francis","year":"2000","journal-title":"Eur J Biochem"},{"key":"88","doi-asserted-by":"crossref","first-page":"12051","DOI":"10.1074\/jbc.M413611200","article-title":"Structural and functional features in human PDE5a1 regulatory domain that provide for allosteric cGMP binding, dimerization, and regulation","volume":"280","author":"Francis","year":"2005","journal-title":"J Biol Chem"},{"key":"89","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1042\/bj3290505","article-title":"Binding of cGMP to both allosteric sites of cGMP-binding cGMP-specific phosphodiesterase (PDE5) is required for its phosphorylation","volume":"329","author":"Corbin","year":"1998","journal-title":"Biochem J"},{"key":"90","doi-asserted-by":"crossref","first-page":"47581","DOI":"10.1074\/jbc.M206088200","article-title":"Phosphorylation of isolated human phosphodiesterase-5 regulatory domain induces an apparent conformational change and increases cGMP binding affinity","volume":"277","author":"Corbin","year":"2002","journal-title":"J Biol Chem"},{"key":"91","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1161\/01.RES.0000256354.95791.f1","article-title":"Overview of PDEs and their regulation","volume":"100","author":"Kotera","year":"2007","journal-title":"Circ Res"},{"key":"92","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.cardiores.2007.02.031","article-title":"Phosphodiesterase regulation of nitric oxide signaling","volume":"75","author":"Champion","year":"2007","journal-title":"Cardiovasc Res"},{"key":"93","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.cellsig.2008.08.012","article-title":"Expression, activity, and pro-hypertrophic effects of PDE5A in cardiac myocytes","volume":"20","author":"Kass","year":"2008","journal-title":"Cell Signal"},{"key":"94","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1161\/CIRCRESAHA.110.226712","article-title":"Feedback control through cGMP-dependent protein kinase contributes to differential regulation and compartmentation of cGMP in rat cardiac myocytes","volume":"107","author":"Fischmeister","year":"2010","journal-title":"Circ Res"},{"key":"95","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.yjmcc.2016.01.004","article-title":"Roles of phosphodiesterases in the regulation of the cardiac cyclic nucleotide cross-talk signaling network","volume":"91","author":"Winslow","year":"2016","journal-title":"J Mol Cell Cardiol"},{"key":"96","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1083\/jcb.200211041","article-title":"Direct activation of PDE5 by cGMP: Long-term effects within NO\/cGMP signaling","volume":"160","author":"Koesling","year":"2003","journal-title":"J Cell Biol"},{"key":"97","doi-asserted-by":"crossref","first-page":"18397","DOI":"10.1074\/jbc.272.29.18397","article-title":"The regulation of the cGMP-binding cGMP phosphodiesterase by proteins that are immunologically related to gamma subunit of the photoreceptor cGMP phosphodiesterase","volume":"272","author":"Pyne","year":"1997","journal-title":"J Biol Chem"},{"key":"98","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/jcp.25880","article-title":"Identification of murine phosphodiesterase 5a isoforms and their functional characterization in hl-1 cardiac cell line","volume":"233","author":"Isidori","year":"2018","journal-title":"J Cell Physiol"},{"key":"99","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/nrm2082","article-title":"Capturing cyclic nucleotides in action: Snapshots from crystallographic studies","volume":"8","author":"Bos","year":"2007","journal-title":"Nat Rev Mol Cell Biol"},{"key":"100","first-page":"137","article-title":"cGMP regulated protein kinases (CGK)","author":"Weinmeister","year":"2009","journal-title":"Handb Exp Pharmacol"},{"key":"101","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1124\/pr.110.002907","article-title":"cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action","volume":"62","author":"Sibley","year":"2010","journal-title":"Pharmacol Rev"},{"key":"102","doi-asserted-by":"crossref","first-page":"23504","DOI":"10.1074\/jbc.273.36.23504","article-title":"Protein kinase g mediates vascular endothelial growth factor-induced RAF-1 activation and proliferation in human endothelial cells","volume":"273","author":"Granger","year":"1998","journal-title":"J Biol Chem"},{"key":"103","doi-asserted-by":"crossref","first-page":"25723","DOI":"10.1074\/jbc.M909632199","article-title":"Regulation of human endothelial cell focal adhesion sites and migration by cGMP-dependent protein kinase i","volume":"275","author":"Lohmann","year":"2000","journal-title":"J Biol Chem"},{"key":"104","doi-asserted-by":"crossref","first-page":"H1388","DOI":"10.1152\/ajpheart.00414.2002","article-title":"Physiological concentration of atrial natriuretic peptide induces endothelial regeneration in vitro","volume":"284","author":"Nakao","year":"2003","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"105","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1161\/CIRCULATIONAHA.106.655266","article-title":"Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility","volume":"116","author":"Michelakis","year":"2007","journal-title":"Circulation"},{"key":"106","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nm1175","article-title":"Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy","volume":"11","author":"Kass","year":"2005","journal-title":"Nat Med"},{"key":"107","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.cellsig.2004.07.007","article-title":"The effect of sildenafil on human platelet secretory function is controlled by a complex interplay between phosphodiesterases 2, 3 and 5","volume":"17","author":"Hatzelmann","year":"2005","journal-title":"Cell Signal"},{"key":"108","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.neuint.2004.03.022","article-title":"Phosphodiesterase type 5 inhibition improves early memory consolidation of object information","volume":"45","author":"Blokland","year":"2004","journal-title":"Neurochem Int"},{"key":"109","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1016\/0006-2952(86)90333-3","article-title":"Selective inhibition of cyclic nucleotide phosphodiesterases of human, bovine and rat aorta","volume":"35","author":"Stoclet","year":"1986","journal-title":"Biochem Pharmacol"},{"key":"110","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1161\/CIRCULATIONAHA.110.944603","article-title":"Drug interactions with phosphodiesterase-5 inhibitors used for the treatment of erectile dysfunction or pulmonary hypertension","volume":"122","author":"Kloner","year":"2010","journal-title":"Circulation"},{"key":"111","first-page":"435","article-title":"Erectile dysfunction: Comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil - review of the literature","volume":"7","author":"Gleiter","year":"2002","journal-title":"Eur J Med Res"},{"key":"112","doi-asserted-by":"crossref","first-page":"4533","DOI":"10.1021\/jm0300577","article-title":"The discovery of tadalafil: A novel and highly selective PDE5 inhibitor 2: 2, 3, 6, 7, 12, 12a-hexahydropyrazino[1\u2032, 2\u2032:1, 6]pyrido[3,4-b]indole-1,4-dione analogues","volume":"46","author":"Labaudiniere","year":"2003","journal-title":"J Med Chem"},{"key":"113","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/sj.ijir.3901283","article-title":"High biochemical selectivity of tadalafil, sildenafil and vardenafil for human phosphodiesterase 5A1 (PDE5) over PDE11A4 suggests the absence of PDE11A4 cross-reaction in patients","volume":"17","author":"Corbin","year":"2005","journal-title":"Int J Impot Res"},{"key":"114","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0090-4295(03)00359-5","article-title":"Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: A randomized controlled trial","volume":"62","author":"Rosen","year":"2003","journal-title":"Urology"},{"key":"115","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.juro.2012.03.115","article-title":"Avanafil, a potent and highly selective phosphodiesterase-5 inhibitor for erectile dysfunction","volume":"188","author":"Omori","year":"2012","journal-title":"J Urol"},{"key":"116","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1111\/j.1365-2125.2008.03107.x","article-title":"Safety, tolerability and pharmacokinetics of udenafil, a novel PDE-5 inhibitor, in healthy young korean subjects","volume":"65","author":"Jang","year":"2008","journal-title":"Br J Clin Pharmacol"},{"key":"117","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1080\/00498250701708521","article-title":"Identification of cytochrome p450 enzymes responsible for n-dealkylation of a new oral erectogenic, mirodenafil","volume":"38","author":"Jang","year":"2008","journal-title":"Xenobiotica"},{"key":"118","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ejphar.2008.06.055","article-title":"Pharmacological characterization of a novel phosphodiesterase type 5 (PDE5) inhibitor lodenafil carbonate on human and rabbit corpus cavernosum","volume":"591","author":"De Nucci","year":"2008","journal-title":"Eur J Pharmacol"},{"key":"119","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/bjp.2008.141","article-title":"Vardenafil, but not sildenafil or tadalafil, has calcium-channel blocking activity in rabbit isolated pulmonary artery and human washed platelets","volume":"154","author":"De Nucci","year":"2008","journal-title":"Br J Pharmacol"},{"key":"120","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.1158\/0008-5472.CAN-10-3820","article-title":"Sildenafil reverses ABCB1- and ABCG2-mediated chemotherapeutic drug resistance","volume":"71","author":"Chen","year":"2011","journal-title":"Cancer Res"},{"key":"121","doi-asserted-by":"crossref","first-page":"3735","DOI":"10.1158\/0008-5472.CAN-11-0375","article-title":"Roles of sildenafil in enhancing drug sensitivity in cancer","volume":"71","author":"Chen","year":"2011","journal-title":"Cancer Res"},{"key":"122","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2147\/CE.S58457","article-title":"Clinical utility of tadalafil in the treatment of pulmonary arterial hypertension: An evidence-based review","volume":"10","author":"Anderson","year":"2015","journal-title":"Core Evid"},{"key":"123","first-page":"257","article-title":"The role of phosphodiesterase inhibitors in the management of pulmonary vascular diseases","volume":"2014","author":"Butrous","year":"2014","journal-title":"Glob Cardiol Sci Pract"},{"key":"124","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1517\/14656566.2011.600306","article-title":"Investigational noncardiovascular uses of phosphodiesterase-5 inhibitors","volume":"12","author":"Stecher","year":"2011","journal-title":"Expert Opin Pharmacother"},{"key":"125","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1016\/j.eururo.2007.01.033","article-title":"Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction","volume":"51","author":"Te","year":"2007","journal-title":"Eur Urol"},{"key":"126","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1111\/j.1743-6109.2008.01109.x","article-title":"Efficacy and safety of combined oral therapy with tadalafil and alfuzosin: An integrated approach to the management of patients with lower urinary tract symptoms and erectile dysfunction. Preliminary report","volume":"6","author":"Belgrano","year":"2009","journal-title":"J Sex Med"},{"key":"127","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00345-009-0484-z","article-title":"Sildenafil citrate and Tamsulosin combination is not superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction","volume":"28","author":"Atan","year":"2010","journal-title":"World J Urol"},{"key":"128","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1111\/j.1743-6109.2008.00940.x","article-title":"Comparative efficacy assessment of Tamsulosin vs. Tamsulosin plus tadalafil in the treatment of LUTS\/BPH. Pilot study","volume":"5","author":"Rey","year":"2008","journal-title":"J Sex Med"},{"key":"129","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1111\/j.1464-410X.2009.08822.x","article-title":"Changes in peak urinary flow and voiding efficiency in men with signs and symptoms of benign prostatic hyperplasia during once daily tadalafil treatment","volume":"105","author":"Viktrup","year":"2010","journal-title":"BJU Int"},{"key":"130","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nrurol.2014.53","article-title":"Microvascular dysfunction and efficacy of PDE5 inhibitors in LUTS\/BPH","volume":"11","author":"Ilo","year":"2014","journal-title":"Nat Rev Urol"},{"key":"131","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nrurol.2010.24","article-title":"Treatment of peyronie's disease with PDE5 inhibitors: An antifibrotic strategy","volume":"7","author":"Rajfer","year":"2010","journal-title":"Nat Rev Urol"},{"key":"132","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1097\/01.ju.0000052403.11923.51","article-title":"Corporoplasty for advanced peyronie's disease using venous and\/or dermis patch grafting: New surgical technique and long-term patient satisfaction","volume":"169","author":"Albers","year":"2003","journal-title":"J Urol"},{"key":"133","first-page":"805","article-title":"Experience with plaque excision and dermal grafting in the surgical treatment of Peyronie's disease","volume":"49","author":"Singh","year":"2008","journal-title":"Singapore Med J"},{"key":"134","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/S0302-2838(03)00378-6","article-title":"Penile corporoplasty using tunica albuginea free graft from proximal corpus cavernosum: A new technique for treatment of penile curvature in Peyronie's disease","volume":"44","author":"Schukai","year":"2003","journal-title":"Eur Urol"},{"key":"135","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1177\/1756287214542096","article-title":"Management of priapism: An update for clinicians","volume":"6","author":"Bivalacqua","year":"2014","journal-title":"Ther Adv Urol"},{"key":"136","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1111\/j.1743-6109.2006.00333.x","article-title":"Feasibility of the use of phosphodiesterase type 5 inhibitors in a pharmacologic prevention program for recurrent priapism","volume":"3","author":"Musicki","year":"2006","journal-title":"J Sex Med"},{"key":"137","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/j.1743-6109.2005.00090.x","article-title":"Case report: Avoidance of palpable corporal fibrosis due to priapism with upregulators of nitric oxide","volume":"3","author":"Gonzalez-Cadavid","year":"2006","journal-title":"J Sex Med"},{"key":"138","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/j.1464-410X.2006.06290.x","article-title":"Efficacy of type-5 phosphodiesterase inhibitors in the drug treatment of premature ejaculation: A systematic review","volume":"98","author":"Winestock","year":"2006","journal-title":"BJU Int"},{"key":"139","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1159\/000112607","article-title":"Tadalafil and fluoxetine in premature ejaculation: Prospective, randomized, double-blind, placebo-controlled study","volume":"80","author":"Srougi","year":"2008","journal-title":"Urol Int"},{"key":"140","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1159\/000102909","article-title":"Effect of fluoxetine alone and in combination with sildenafil in patients with premature ejaculation","volume":"79","author":"Yarmohammadi","year":"2007","journal-title":"Urol Int"},{"key":"141","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1111\/j.1464-410X.2010.09243.x","article-title":"Effects of phosphodiesterase-5 inhibitors on Leydig cell secretory function in oligoasthenospermic infertile men: A randomized trial","volume":"106","author":"Sofikitis","year":"2010","journal-title":"BJU Int"},{"key":"142","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.fertnstert.2006.11.017","article-title":"Sildenafil citrate improves sperm motility but causes a premature acrosome reaction in vitro","volume":"87","author":"Lewis","year":"2007","journal-title":"Fertil Steril"},{"key":"143","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/sj.ijir.3901377","article-title":"Phosphodiesterase 11 (PDE11): Is it a player in human testicular function?","volume":"17","author":"Francis","year":"2005","journal-title":"Int J Impot Res"},{"key":"144","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.fertnstert.2006.12.019","article-title":"Alterations in sperm motility after acute oral administration of sildenafil or tadalafil in young, infertile men","volume":"88","author":"Francesca","year":"2007","journal-title":"Fertil Steril"},{"key":"145","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1439-0272.2006.00752.x","article-title":"Tadalafil as an in vitro sperm motility stimulant","volume":"39","author":"Mostafa","year":"2007","journal-title":"Andrologia"},{"key":"146","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.brainres.2006.08.028","article-title":"Tadalafil, a long-acting type 5 phosphodiesterase isoenzyme inhibitor, improves neurological functional recovery in a rat model of embolic stroke","volume":"1118","author":"Chopp","year":"2006","journal-title":"Brain Res"},{"key":"147","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1002\/jnr.20813","article-title":"Delayed treatment with sildenafil enhances neurogenesis and improves functional recovery in aged rats after focal cerebral ischemia","volume":"83","author":"Chopp","year":"2006","journal-title":"J Neurosci Res"},{"key":"148","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1038\/jcbfm.2008.33","article-title":"Magnetic resonance imaging investigation of axonal remodeling and angiogenesis after embolic stroke in sildenafil-treated rats","volume":"28","author":"Chopp","year":"2008","journal-title":"J Cereb Blood Flow Metab"},{"key":"149","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.jstrokecerebrovasdis.2009.01.007","article-title":"Sildenafil treatment of subacute ischemic stroke: A safety study at 25-mg daily for 2 weeks","volume":"18","author":"Chopp","year":"2009","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"150","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1111\/j.1476-5381.2011.01517.x","article-title":"Sildenafil restores cognitive function without affecting \u03b2-amyloid burden in a mouse model of Alzheimer's disease","volume":"164","author":"Garcia-Osta","year":"2011","journal-title":"Br J Pharmacol"},{"key":"151","doi-asserted-by":"crossref","first-page":"8075","DOI":"10.1523\/JNEUROSCI.0864-09.2009","article-title":"Phosphodiesterase 5 inhibition improves synaptic function, memory, and amyloid-beta load in an Alzheimer's disease mouse model","volume":"29","author":"Arancio","year":"2009","journal-title":"J Neurosci"},{"key":"152","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s00213-008-1278-5","article-title":"A placebo-controlled study of sildenafil effects on cognition in Schizophrenia","volume":"202","author":"Walsh","year":"2009","journal-title":"Psychopharmacology (Berl)"},{"key":"153","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s00213-007-0999-1","article-title":"Selective PDE inhibitors rolipram and sildenafil improve object retrieval performance in adult cynomolgus macaques","volume":"196","author":"Vivian","year":"2008","journal-title":"Psychopharmacology (Berl)"},{"key":"154","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1124\/jpet.110.170191","article-title":"Long-acting phosphodiesterase-5 inhibitor tadalafil attenuates doxorubicin-induced cardiomyopathy without interfering with chemotherapeutic effect","volume":"334","author":"Kukreja","year":"2010","journal-title":"J Pharmacol Exp Ther"},{"key":"155","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1161\/01.CIR.0000160359.49478.C2","article-title":"Phosphodiesterase-5 inhibition with sildenafil attenuates cardiomyocyte apoptosis and left ventricular dysfunction in a chronic model of doxorubicin cardiotoxicity","volume":"111","author":"Kukreja","year":"2005","journal-title":"Circulation"},{"key":"156","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1124\/mol.113.090043","article-title":"Phosphodiesterase 5 inhibitors enhance chemotherapy killing in gastrointestinal\/genitourinary cancer cells","volume":"85","author":"Dent","year":"2014","journal-title":"Mol Pharmacol"},{"key":"157","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.tox.2008.12.017","article-title":"Sildenafil attenuates renal injury in an experimental model of rat cisplatin-induced nephrotoxicity","volume":"257","author":"Choi","year":"2009","journal-title":"Toxicology"},{"key":"158","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/sj.bjp.0707605","article-title":"Role of the NO\/cGMP\/K(ATP) pathway in the protective effects of sildenafil against ethanol-induced gastric damage in rats","volume":"153","author":"Souza","year":"2008","journal-title":"Br J Pharmacol"},{"key":"159","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1007\/s10620-008-0646-7","article-title":"Sildenafil, an inhibitor of phosphodiesterase subtype 5, prevents indomethacin-induced small-intestinal ulceration in rats via a NO\/cGMP-dependent mechanism","volume":"54","author":"Takeuchi","year":"2009","journal-title":"Dig Dis Sci"},{"key":"160","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ejphar.2009.03.038","article-title":"The effects of sildenafil on the functional and structural changes of ileum induced by intestinal ischemia-reperfusion in rats","volume":"610","author":"Tuncer","year":"2009","journal-title":"Eur J Pharmacol"},{"key":"161","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1191\/0961203303lu257cr","article-title":"Treatment with sildenafil for the healing of refractory skin ulcerations in the antiphospholipid syndrome","volume":"12","author":"Gertner","year":"2003","journal-title":"Lupus"},{"key":"162","first-page":"2440","article-title":"Severe refractory fingertip ulcerations in a patient with scleroderma: Successful treatment with sildenafil","volume":"32","author":"O\u2019Rourke","year":"2005","journal-title":"J Rheumatol"},{"key":"163","first-page":"392542","article-title":"PDE-5 inhibitors in scleroderma Raynaud phenomenon and digital ulcers: Current status of clinical trials","volume":"2011","author":"Schiopu","year":"2011","journal-title":"Int J Rheumatol"},{"key":"164","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1136\/annrheumdis-2012-202836","article-title":"Phosphodiesterase-5 inhibitors for the treatment of secondary Raynaud's phenomenon: Systematic review and meta-analysis of randomised trials","volume":"72","author":"Cracowski","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"165","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1161\/CIRCULATIONAHA.104.523324","article-title":"Sildenafil in the treatment of raynaud's phenomenon resistant to vasodilatory therapy","volume":"112","author":"Bohm","year":"2005","journal-title":"Circulation"},{"key":"166","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1136\/ard.2009.116475","article-title":"Effect of sildenafil on digital ulcers in systemic sclerosis: Analysis from a single centre pilot study","volume":"69","author":"Riemekasten","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"167","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/BOR.0000000000000172","article-title":"Systemic sclerosis: A systematic review on therapeutic management from 2011 to 2014","volume":"27","author":"Khanna","year":"2015","journal-title":"Curr Opin Rheumatol"},{"key":"168","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.healun.2009.04.013","article-title":"Acute hemodynamic effects of intravenous sildenafil citrate in congestive heart failure: Comparison of phosphodiesterase type-3 and -5 inhibition","volume":"28","author":"Macgowan","year":"2009","journal-title":"J Heart Lung Transplant"},{"key":"169","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1016\/j.transproceed.2007.08.077","article-title":"Use of sildenafil in heart transplant recipients with pulmonary hypertension may prevent right heart failure","volume":"39","author":"Zembala","year":"2007","journal-title":"Transplant Proc"},{"key":"170","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1016\/j.transproceed.2008.05.055","article-title":"Role of sildenafil in acute posttransplant right ventricular dysfunction: Successful experience in 13 consecutive patients","volume":"40","author":"Caianiello","year":"2008","journal-title":"Transplant Proc"},{"key":"171","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/lt.21310","article-title":"Safety and efficacy of combined use of sildenafil, bosentan, and iloprost before and after liver transplantation in severe portopulmonary hypertension","volume":"14","author":"Heneghan","year":"2008","journal-title":"Liver Transpl"},{"key":"172","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/S1665-2681(19)31798-3","article-title":"The use of sildenafil to treat portopulmonary hypertension prior to liver transplantation","volume":"8","author":"Yoshida","year":"2009","journal-title":"Ann Hepatol"},{"key":"173","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/lt.21533","article-title":"Sildenafil therapy is associated with improved hemodynamics in liver transplantation candidates with pulmonary arterial hypertension","volume":"15","author":"White","year":"2009","journal-title":"Liver Transpl"},{"key":"174","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/lt.21479","article-title":"Sildenafil monotherapy in portopulmonary hypertension can facilitate liver transplantation","volume":"15","author":"Robbins","year":"2009","journal-title":"Liver Transpl"},{"key":"175","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1111\/jsm.12038","article-title":"Phosphodiesterase type 5 inhibitor treatment for erectile dysfunction in patients with end-stage renal disease receiving dialysis or after renal transplantation","volume":"10","author":"Fontana","year":"2013","journal-title":"J Sex Med"},{"key":"176","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.ejcts.2009.01.015","article-title":"Improvement of pulmonary microcirculation after lung transplantation using phosphodiesterase-5 inhibitor modified preservation solution","volume":"35","author":"Kamler","year":"2009","journal-title":"Eur J Cardiothorac Surg"},{"key":"177","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1007\/s00266-008-9166-2","article-title":"Evaluation of the effect of sildenafil and vascular endothelium growth factor combination treatment on skin flap survival in rats","volume":"32","author":"Pizarro","year":"2008","journal-title":"Aesthetic Plast Surg"},{"key":"178","doi-asserted-by":"crossref","first-page":"358","DOI":"10.3109\/2000656X.2015.1041024","article-title":"Comparison of the effects of systemic sildenafil, tadalafil, and vardenafil treatments on skin flap survival in rats","volume":"49","author":"Ergun","year":"2015","journal-title":"J Plast Surg Hand Surg"},{"key":"179","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s00345-005-0015-5","article-title":"Phosphodiesterase inhibitors in female sexual dysfunction","volume":"23","author":"Uckert","year":"2005","journal-title":"World J Urol"},{"key":"180","first-page":"99","article-title":"Neither sildenafil nor vaginal estradiol improves endometrial thickness in women with thin endometria after taking oral estradiol in graduating dosages","volume":"31","author":"Dietterich","year":"2004","journal-title":"Clin Exp Obstet Gynecol"},{"key":"181","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1016\/j.fertnstert.2007.08.043","article-title":"Sildenafil citrate decreased natural killer cell activity and enhanced chance of successful pregnancy in women with a history of recurrent miscarriage","volume":"90","author":"Baranowski","year":"2008","journal-title":"Fertil Steril"},{"key":"182","first-page":"1433","article-title":"Biochemical role of intravaginal sildenafil citrate as a novel antiabortive agent in unexplained recurrent spontaneous miscarriage: First clinical study of four case reports from Egypt","volume":"47","author":"Bakry","year":"2009","journal-title":"Clin Chem Lab Med"},{"key":"183","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1093\/humrep\/15.4.806","article-title":"Vaginal sildenafil (viagra): A preliminary report of a novel method to improve uterine artery blood flow and endometrial development in patients undergoing IVF","volume":"15","author":"Fisch","year":"2000","journal-title":"Hum Reprod"},{"key":"184","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/S0015-0282(02)04162-6","article-title":"Effect of vaginal sildenafil on the outcome of in vitro fertilization (ivf) after multiple ivf failures attributed to poor endometrial development","volume":"78","author":"Fisch","year":"2002","journal-title":"Fertil Steril"},{"key":"185","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s11906-011-0204-0","article-title":"Mechanisms and potential therapies for preeclampsia","volume":"13","author":"Granger","year":"2011","journal-title":"Curr Hypertens Rep"},{"key":"186","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.ejphar.2008.04.034","article-title":"The effect of sildenafil on the altered thoracic aorta smooth muscle responses in rat pre-eclampsia model","volume":"589","author":"Karadas","year":"2008","journal-title":"Eur J Pharmacol"},{"key":"187","doi-asserted-by":"crossref","first-page":"369","DOI":"10.3109\/10641950802601278","article-title":"A randomised, double-blinded, placebo-controlled study of the phosphodiesterase type 5 inhibitor sildenafil for the treatment of preeclampsia","volume":"28","author":"Baker","year":"2009","journal-title":"Hypertens Pregnancy"},{"key":"188","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1111\/j.1742-1241.2006.01087.x","article-title":"PDE5 inhibitors in diabetic peripheral neuropathy","volume":"60","author":"Hackett","year":"2006","journal-title":"Int J Clin Pract"},{"key":"189","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.neuroscience.2011.07.039","article-title":"Phosphodiesterase-5 is a therapeutic target for peripheral neuropathy in diabetic mice","volume":"193","author":"Zhang","year":"2011","journal-title":"Neuroscience"},{"key":"190","doi-asserted-by":"crossref","first-page":"218","DOI":"10.4103\/1673-5374.200804","article-title":"PDE5 inhibitors promote recovery of peripheral neuropathy in diabetic mice","volume":"12","author":"Zhang","year":"2017","journal-title":"Neural Regen Res"},{"key":"191","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1159\/000080104","article-title":"Modulatory effect of the PDE-5 inhibitor sildenafil in diabetic neuropathy","volume":"72","author":"Kulkarni","year":"2004","journal-title":"Pharmacology"},{"key":"192","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.2337\/diacare.25.8.1336","article-title":"Acute and prolonged effects of sildenafil on brachial artery flow-mediated dilatation in type 2 diabetes","volume":"25","author":"Fonseca","year":"2002","journal-title":"Diabetes Care"},{"key":"193","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1177\/1756287209344992","article-title":"Testosterone and phosphodiesterase type-5 inhibitors: New strategy for preventing endothelial damage in internal and sexual medicine?","volume":"1","author":"Lenzi","year":"2009","journal-title":"Ther Adv Urol"},{"key":"194","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1464-5491.2007.02298.x","article-title":"Chronic administration of sildenafil improves markers of endothelial function in men with type 2 diabetes","volume":"25","author":"Rosano","year":"2008","journal-title":"Diabet Med"},{"key":"195","doi-asserted-by":"crossref","first-page":"290","DOI":"10.4103\/1008-682X.122347","article-title":"Tadalafil treatment had a modest effect on endothelial cell damage and repair ability markers in men with erectile dysfunction and vascular risk","volume":"16","author":"Francavilla","year":"2014","journal-title":"Asian J Androl"},{"key":"196","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.diabres.2007.02.006","article-title":"Sildenafil citrate diminishes microalbuminuria and the percentage of A1C in male patients with type 2 diabetes","volume":"78","author":"Guillen Ortiz","year":"2007","journal-title":"Diabetes Res Clin Pract"},{"key":"197","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/nrurol.2010.165","article-title":"An update on new oral PDE5 inhibitors for the treatment of erectile dysfunction","volume":"7","author":"Eardley","year":"2010","journal-title":"Nat Rev Urol"},{"key":"198","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/j.1743-6109.2009.01627.x","article-title":"Pharmacotherapy for erectile dysfunction","volume":"7","author":"Lee","year":"2010","journal-title":"J Sex Med"},{"key":"199","doi-asserted-by":"crossref","first-page":"139","DOI":"10.4065\/84.2.139","article-title":"Erectile dysfunction and cardiovascular disease: Efficacy and safety of phosphodiesterase type 5 inhibitors in men with both conditions","volume":"84","author":"Nehra","journal-title":"Mayo Clin Proc"},{"key":"200","first-page":"584","article-title":"Non-small cell lung cancer: Epidemiology, risk factors, treatment, and survivorship","volume":"83","author":"Adjei","journal-title":"Mayo Clin Proc"},{"key":"201","first-page":"2909","article-title":"Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels","volume":"57","author":"Burt","year":"1997","journal-title":"Cancer Res"},{"key":"202","first-page":"3338","article-title":"Exisulind induction of apoptosis involves guanosine 3\u2019,5\u2019-cyclic monophosphate phosphodiesterase inhibition, protein kinase g activation, and attenuated beta-catenin","volume":"60","author":"Pamukcu","year":"2000","journal-title":"Cancer Res"},{"key":"203","first-page":"4136","article-title":"Cyclic GMP mediates apoptosis induced by sulindac derivatives via activation of c-JUN NH2-terminal kinase 1","volume":"6","author":"Weinstein","year":"2000","journal-title":"Clin Cancer Res"},{"key":"204","first-page":"6178","article-title":"Synergistic effects of new chemopreventive agents and conventional cytotoxic agents against human lung cancer cell lines","volume":"59","author":"Chou","year":"1999","journal-title":"Cancer Res"},{"key":"205","first-page":"904","article-title":"Exisulind in combination with docetaxel inhibits growth and metastasis of human lung cancer and prolongs survival in athymic nude rats with orthotopic lung tumors","volume":"8","author":"Bunn","year":"2002","journal-title":"Clin Cancer Res"},{"key":"206","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1053\/sonc.2002.31529","article-title":"Preclinical and clinical studies of docetaxel and exisulind in the treatment of human lung cancer","volume":"29","author":"Alila","year":"2002","journal-title":"Semin Oncol"},{"key":"207","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s11095-013-1134-0","article-title":"Pharmacological modulation of cytotoxicity and cellular uptake of anti-cancer drugs by PDE5 inhibitors in lung cancer cells","volume":"31","author":"Shu","year":"2014","journal-title":"Pharm Res"},{"key":"208","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.18632\/oncotarget.13640","article-title":"PDE5 inhibitors enhance the lethality of pemetrexed through inhibition of multiple chaperone proteins and via the actions of cyclic GMP and nitric oxide","volume":"8","author":"Dent","year":"2017","journal-title":"Oncotarget"},{"key":"209","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/S1556-0864(15)31571-9","article-title":"Phase I\/II study of gemcitabine and exisulind as second-line therapy in patients with advanced non-small cell lung cancer","volume":"1","author":"Schiller","year":"2006","journal-title":"J Thorac Oncol"},{"key":"210","doi-asserted-by":"crossref","first-page":"361","DOI":"10.3816\/CLC.2005.n.016","article-title":"A phase I\/II study of exisulind in combination with docetaxel\/carboplatin in patients with metastatic non-small-cell lung cancer","volume":"6","author":"Burris","year":"2005","journal-title":"Clin Lung Cancer"},{"key":"211","first-page":"673","article-title":"A phase II trial of carboplatin and gemcitabine with exisulind (IND #65,056) in patients with advanced non-small cell lung cancer: an Eastern Cooperative Oncology Group Study (E1501)","volume":"1","author":"Johnson","year":"2006","journal-title":"J Thorac Oncol"},{"key":"212","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1097\/JTO.0b013e3181462051","article-title":"Docetaxel and exisulind in previously treated non-small cell lung cancer (NSCLC) patients: A multicenter, phase II clinical trial","volume":"2","author":"Kelly","year":"2007","journal-title":"J Thorac Oncol"},{"key":"213","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/JTO.0b013e3181951eb0","article-title":"A phase II study of carboplatin, etoposide, and exisulind in patients with extensive small cell lung cancer: CALGB 30104","volume":"4","author":"Green","year":"2009","journal-title":"J Thorac Oncol"},{"key":"214","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/S0090-4295(98)00513-5","article-title":"Exisulind (sulindac sulfone) suppresses growth of human prostate cancer in a nude mouse xenograft model by increasing apoptosis","volume":"53","author":"Olsson","year":"1999","journal-title":"Urology"},{"key":"215","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1097\/01.ju.0000080321.99119.df","article-title":"Effect of sildenafil citrate on an orthotopic prostate cancer growth and metastasis model","volume":"170","author":"Teh","year":"2003","journal-title":"J Urol"},{"key":"216","doi-asserted-by":"crossref","first-page":"18202","DOI":"10.1073\/pnas.1006965107","article-title":"Sildenafil increases chemotherapeutic efficacy of doxorubicin in prostate cancer and ameliorates cardiac dysfunction","volume":"107","author":"Kukreja","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"217","doi-asserted-by":"publisher","first-page":"4399","DOI":"10.18632\/oncotarget.6749","article-title":"Sildenafil (viagra) sensitizes prostate cancer cells to doxorubicin-mediated apoptosis through CD95","volume":"7","author":"Kukreja","year":"2016","journal-title":"Oncotarget"},{"key":"218","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.canlet.2016.05.010","article-title":"Phosphodiesterase 5\/Protein Kinase G signal governs stemness of prostate cancer stem cells through hippo pathway","volume":"378","author":"Wu","year":"2016","journal-title":"Cancer Lett"},{"key":"219","doi-asserted-by":"crossref","first-page":"3975","DOI":"10.1210\/en.2009-1411","article-title":"Attenuated proliferation and trans-differentiation of prostatic stromal cells indicate suitability of phosphodiesterase type 5 inhibitors for prevention and treatment of benign prostatic hyperplasia","volume":"151","author":"Berger","year":"2010","journal-title":"Endocrinology"},{"key":"220","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/MOU.0b013e328333ac68","article-title":"Phosphodiesterase-5 inhibitors and benign prostatic hyperplasia","volume":"20","author":"Wang","year":"2010","journal-title":"Curr Opin Urol"},{"key":"221","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/aja.2012.162","article-title":"Incidence rate of prostate cancer in men treated for erectile dysfunction with phosphodiesterase type 5 inhibitors: Retrospective analysis","volume":"15","author":"Jo","year":"2013","journal-title":"Asian J Androl"},{"key":"222","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1038\/onc.2008.476","article-title":"Hypoxia-associated p38 mitogen-activated protein kinase-mediated androgen receptor activation and increased HIF-1 alpha levels contribute to emergence of an aggressive phenotype in prostate cancer","volume":"28","author":"Koul","year":"2009","journal-title":"Oncogene"},{"key":"223","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1002\/1097-0142(20001101)89:9<2018::AID-CNCR19>3.3.CO;2-P","article-title":"Increasing levels of hypoxia in prostate carcinoma correlate significantly with increasing clinical stage and patient age: an Eppendorf pO(2) study","volume":"89","author":"Hanks","year":"2000","journal-title":"Cancer"},{"key":"224","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s00345-012-0848-7","article-title":"Potential therapeutic applications of phosphodiesterase inhibition in prostate cancer","volume":"31","author":"Siemens","year":"2013","journal-title":"World J Urol"},{"key":"225","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/S0022-5347(05)65856-9","article-title":"Safety and efficacy of exisulind for treatment of recurrent prostate cancer after radical prostatectomy","volume":"166","author":"Network","year":"2001","journal-title":"J Urol"},{"key":"226","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.juro.2014.08.111","article-title":"Use of phosphodiesterase type 5 inhibitors may adversely impact biochemical recurrence after radical prostatectomy","volume":"193","author":"Steuber","year":"2015","journal-title":"J Urol"},{"key":"227","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.eururo.2015.02.002","article-title":"A detailed analysis of the association between postoperative phosphodiesterase type 5 inhibitor use and the risk of biochemical recurrence after radical prostatectomy","volume":"68","author":"Briganti","year":"2015","journal-title":"Eur Urol"},{"key":"228","doi-asserted-by":"crossref","first-page":"e91327","DOI":"10.1371\/journal.pone.0091327","article-title":"Systematic review and meta-analysis of the use of phosphodiesterase type 5 inhibitors for treatment of erectile dysfunction following bilateral nerve-sparing radical prostatectomy","volume":"9","author":"Zhang","year":"2014","journal-title":"PLoS One"},{"key":"229","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/35021093","article-title":"Molecular portraits of human breast tumours","volume":"406","author":"Williams","year":"2000","journal-title":"Nature"},{"key":"230","doi-asserted-by":"crossref","first-page":"3331","DOI":"10.1158\/1535-7163.MCT-09-0758","article-title":"Sulindac sulfide selectively inhibits growth and induces apoptosis of human breast tumor cells by phosphodiesterase 5 inhibition, elevation of cyclic GMP, and activation of protein kinase G","volume":"8","author":"Piazza","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"231","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1158\/1940-6207.CAPR-11-0095","article-title":"Inhibition of PDE5 by sulindac sulfide selectively induces apoptosis and attenuates oncogenic Wnt\/\u03b2-catenin-mediated transcription in human breast tumor cells","volume":"4","author":"Piazza","year":"2011","journal-title":"Cancer Prev Res (Phila)"},{"key":"232","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s10585-014-9667-0","article-title":"Identification and validation of genes with expression patterns inverse to multiple metastasis suppressor genes in breast cancer cell lines","volume":"31","author":"Steeg","year":"2014","journal-title":"Clin Exp Metastasis"},{"key":"233","first-page":"267","article-title":"Sulfone metabolite of sulindac inhibits mammary carcinogenesis","volume":"57","author":"Ahnen","year":"1997","journal-title":"Cancer Res"},{"key":"234","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.arcmed.2012.08.006","article-title":"Evaluation of PDE5 and PDE9 expression in benign and malignant breast tumors","volume":"43","author":"Atri","year":"2012","journal-title":"Arch Med Res"},{"key":"235","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0022-3565(24)29266-1","article-title":"Cyclic GMP-dependent protein kinase activation and induction by exisulind and CP461 in colon tumor cells","volume":"299","author":"Thompson","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"236","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1158\/1940-6207.CAPR-11-0559","article-title":"A novel sulindac derivative that potently suppresses colon tumor cell growth by inhibiting cGMP phosphodiesterase and \u03b2-catenin transcriptional activity","volume":"5","author":"Piazza","year":"2012","journal-title":"Cancer Prev Res (Phila)"},{"key":"237","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1158\/1535-7163.MCT-13-0048","article-title":"Sulindac selectively inhibits colon tumor cell growth by activating the cGMP\/PKG pathway to suppress Wnt\/\u03b2-catenin signaling","volume":"12","author":"Chang","year":"2013","journal-title":"Mol Cancer Ther"},{"key":"238","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1158\/1940-6207.CAPR-10-0030","article-title":"Colon tumor cell growth-inhibitory activity of sulindac sulfide and other nonsteroidal anti-inflammatory drugs is associated with phosphodiesterase 5 inhibition","volume":"3","author":"Piazza","year":"2010","journal-title":"Cancer Prev Res (Phila)"},{"key":"239","first-page":"1541","article-title":"Inhibition of extracellular signal-regulated kinase 1\/2 phosphorylation and induction of apoptosis by sulindac metabolites","volume":"61","author":"Ahnen","year":"2001","journal-title":"Cancer Res"},{"key":"240","doi-asserted-by":"crossref","first-page":"8148","DOI":"10.1158\/0008-5472.CAN-04-1517","article-title":"Inhibition of extracellular-signal regulated kinases 1\/2 is required for apoptosis of human colon cancer cells in vitro by sulindac metabolites","volume":"64","author":"Ahnen","year":"2004","journal-title":"Cancer Res"},{"key":"241","first-page":"3311","article-title":"Sildenafil inhibits the growth of human colorectal cancer in vitro and in vivo","volume":"5","author":"Wei","year":"2015","journal-title":"Am J Cancer Res"},{"key":"242","doi-asserted-by":"publisher","first-page":"27403","DOI":"10.18632\/oncotarget.4741","article-title":"Suppression of \u03b2-catenin\/TCF transcriptional activity and colon tumor cell growth by dual inhibition of PDE5 and 10","volume":"6","author":"Wierzbicki","year":"2015","journal-title":"Oncotarget"},{"key":"243","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/978-1-4615-4149-3_5","article-title":"Sulindac sulfone induced regression of rectal polyps in patients with familial adenomatous polyposis","volume":"470","author":"Kelloff","year":"1999","journal-title":"Adv Exp Med Biol"},{"key":"244","first-page":"78","article-title":"Phase I trial of exisulind (sulindac sulfone, FGN-1) as a chemopreventive agent in patients with familial adenomatous polyposis","volume":"6","author":"Hawk","year":"2000","journal-title":"Clin Cancer Res"},{"key":"245","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1158\/1940-6207.CAPR-17-0015","article-title":"Sildenafil suppresses inflammation-driven colorectal cancer in mice","volume":"10","author":"Browning","year":"2017","journal-title":"Cancer Prev Res (Phila)"},{"key":"246","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1158\/1940-6207.CAPR-17-0136","article-title":"Validation of PDE5 as a chemoprevention target","volume":"10","author":"Piazza","year":"2017","journal-title":"Cancer Prev Res (Phila)"},{"key":"247","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/S0014-5793(99)00227-6","article-title":"cAMP-dependent induction of PDE5 expression in murine neuroblastoma cell differentiation","volume":"446","author":"Augusti-Tocco","year":"1999","journal-title":"FEBS Lett"},{"key":"248","doi-asserted-by":"crossref","first-page":"758","DOI":"10.4161\/cbt.28553","article-title":"PDE5 inhibitors enhance the lethality of standard of care chemotherapy in pediatric CNS tumor cells","volume":"15","author":"Dent","year":"2014","journal-title":"Cancer Biol Ther"},{"key":"249","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.brainres.2008.06.122","article-title":"PDE5 inhibitors enhance tumor permeability and efficacy of chemotherapy in a rat brain tumor model","volume":"1230","author":"Shu","year":"2008","journal-title":"Brain Res"},{"key":"250","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1002\/jcp.24977","article-title":"OSU-03012 and Vagra treatment inhibits the activity of multiple chaperone proteins and disrupts the blood-brain barrier: Implications for anti-cancer therapies","volume":"230","author":"Dent","year":"2015","journal-title":"J Cell Physiol"},{"key":"251","doi-asserted-by":"crossref","first-page":"e10108","DOI":"10.1371\/journal.pone.0010108","article-title":"Phosphodiesterase type 5 inhibitors increase herceptin transport and treatment efficacy in mouse metastatic brain tumor models","volume":"5","author":"Black","year":"2010","journal-title":"PLoS One"},{"key":"252","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s11060-014-1690-0","article-title":"Phosphodiesterase type 5 inhibitor tadalafil increases rituximab treatment efficacy in a mouse brain lymphoma model","volume":"122","author":"Mao","year":"2015","journal-title":"J Neurooncol"},{"key":"253","doi-asserted-by":"publisher","first-page":"13223","DOI":"10.18632\/oncotarget.14656","article-title":"Type 5 phosphodiesterase regulates glioblastoma multiforme aggressiveness and clinical outcome","volume":"8","author":"Dolci","year":"2017","journal-title":"Oncotarget"},{"key":"254","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: Sources, methods and major patterns in Globocan 2012","volume":"136","author":"Bray","year":"2015","journal-title":"Int J Cancer"},{"key":"255","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/S0140-6736(03)12488-9","article-title":"Thyroid carcinoma","volume":"361","author":"Sherman","year":"2003","journal-title":"Lancet"},{"key":"256","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/ncpendmet0449","article-title":"Defects in iodide metabolism in thyroid cancer and implications for the follow-up and treatment of patients","volume":"3","author":"Bidart","year":"2007","journal-title":"Nat Clin Pract Endocrinol Metab"},{"key":"257","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.1097\/RLU.0b013e31823905e4","article-title":"Correlation of clinicopathological features and expression of molecular markers with prognosis after 131I treatment of differentiated thyroid carcinoma","volume":"37","author":"An","year":"2012","journal-title":"Clin Nucl Med"},{"key":"258","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.neuropharm.2010.05.004","article-title":"Quantitative comparison of phosphodiesterase mRNA distribution in human brain and peripheral tissues","volume":"59","author":"Boess","year":"2010","journal-title":"Neuropharmacology"},{"key":"259","first-page":"2872","article-title":"Induction of specific phosphodiesterase isoforms by constitutive activation of the cAMP pathway in autonomous thyroid adenomas","volume":"85","author":"Conti","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"260","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1007\/s12020-015-0586-x","article-title":"PDE5 expression in human thyroid tumors and effects of PDE5 inhibitors on growth and migration of cancer cells","volume":"50","author":"Russo","year":"2015","journal-title":"Endocrine"},{"key":"261","doi-asserted-by":"crossref","first-page":"7511","DOI":"10.1158\/1078-0432.CCR-11-1155","article-title":"Role of braf in thyroid oncogenesis","volume":"17","author":"Shah","year":"2011","journal-title":"Clin Cancer Res"},{"key":"262","first-page":"599","article-title":"Does cyclic guanosine monophosphate induce autophagy in thyroid malignant carcinoma through down-regulation of cyclic guanosine monophosphate phosphodiesterase?","volume":"30","author":"Petrini","year":"2016","journal-title":"J Biol Regul Homeost Agents"},{"key":"263","first-page":"1","article-title":"PDE5 inhibitors-loaded nanovesicles: Physico-chemical properties and in vitro antiproliferative activity","volume":"6","author":"Russo","year":"2016","journal-title":"Nanomaterials"},{"key":"264","first-page":"500","article-title":"Cutaneous malignant melanoma","volume":"81","author":"Chanmugam","journal-title":"Mayo Clin Proc"},{"key":"265","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/j.1939-1676.2003.tb02513.x","article-title":"The basic biology of malignant melanoma: Molecular mechanisms of disease progression and comparative aspects","volume":"17","author":"Kitchell","year":"2003","journal-title":"J Vet Intern Med"},{"key":"266","first-page":"355","article-title":"Expression and role of phosphodiesterase 5 in human malignant melanoma cell line","volume":"30","author":"Tagawa","year":"2010","journal-title":"Anticancer Res"},{"key":"267","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ccr.2010.10.029","article-title":"Oncogenic BRAF induces melanoma cell invasion by downregulating the cGMP-specific phosphodiesterase PDE5A","volume":"19","author":"Marais","year":"2011","journal-title":"Cancer Cell"},{"key":"268","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1016\/j.celrep.2016.02.028","article-title":"Sildenafil potentiates a cGMP-dependent pathway to promote melanoma growth","volume":"14","author":"Feil","year":"2016","journal-title":"Cell Rep"},{"key":"269","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1001\/jamainternmed.2014.594","article-title":"Sildenafil use and increased risk of incident melanoma in US men: a prospective cohort study","volume":"174","author":"Han","year":"2014","journal-title":"JAMA Intern Med"},{"key":"270","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1001\/jama.2015.6604","article-title":"Use of phosphodiesterase type 5 inhibitors for erectile dysfunction and risk of malignant melanoma","volume":"313","author":"Stattin","year":"2015","journal-title":"JAMA"},{"key":"271","doi-asserted-by":"crossref","first-page":"e1002037","DOI":"10.1371\/journal.pmed.1002037","article-title":"Phosphodiesterase type 5 inhibitors and risk of malignant melanoma: matched cohort study using primary care data from the UK clinical practice research datalink","volume":"13","author":"Bhaskaran","year":"2016","journal-title":"PLoS Med"},{"key":"272","doi-asserted-by":"publisher","first-page":"46461","DOI":"10.18632\/oncotarget.17518","article-title":"Relation of phosphodiesterase type 5 inhibitors and malignant melanoma: A meta-analysis and systematic review","volume":"8","author":"Ji","year":"2017","journal-title":"Oncotarget"},{"key":"273","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.3892\/ijmm.2014.1925","article-title":"Essential role of the cGMP\/PKG signaling pathway in regulating the proliferation and survival of human renal carcinoma cells","volume":"34","author":"Wu","year":"2014","journal-title":"Int J Mol Med"},{"key":"274","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1002\/cam4.642","article-title":"C-type natriuretic peptide in combination with sildenafil attenuates proliferation of rhabdomyosarcoma cells","volume":"5","author":"Kangawa","year":"2016","journal-title":"Cancer Med"},{"key":"275","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1182\/blood-2002-01-0075","article-title":"Sildenafil and vardenafil, types 5 and 6 phosphodiesterase inhibitors, induce caspase-dependent apoptosis of B-chronic lymphocytic leukemia cells","volume":"101","author":"Merle-Beral","year":"2003","journal-title":"Blood"},{"key":"276","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1016\/j.febslet.2013.07.041","article-title":"Phosphodiesterase 5 inhibitor acts as a potent agent sensitizing acute myeloid leukemia cells to 67-kDa laminin receptor-dependent apoptosis","volume":"587","author":"Tachibana","year":"2013","journal-title":"FEBS Lett"},{"key":"277","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1111\/bjh.13135","article-title":"Vardenafil, a clinically available phosphodiesterase inhibitor, potentiates the killing effect of EGCG on CLL cells","volume":"168","author":"Tachibana","year":"2015","journal-title":"Br J Haematol"},{"key":"278","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1158\/2326-6066.CIR-13-0213","article-title":"Targeting immune suppression with PDE5 inhibition in end-stage multiple myeloma","volume":"2","author":"Borrello","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"279","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1158\/1078-0432.CCR-14-1716","article-title":"Tadalafil augments tumor specific immunity in patients with head and neck squamous cell carcinoma","volume":"21","author":"Tang","year":"2015","journal-title":"Clin Cancer Res"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.21837","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T14:28:05Z","timestamp":1750948085000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.21837"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,12]]},"references-count":279,"journal-issue":{"issue":"58","published-print":{"date-parts":[[2017,11,17]]}},"alternative-id":["21837","29228762"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.21837","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,12]]}}}